• A clinical stage newly public biotech client desired a quantitative indication prioritization methodology to guide clinical development of a promising early-stage agent with a novel CNS mechanism.
• Analysis should span technical / scientific, clinical, and commercial factors
• Indications being considered ranged from those with high prevalence and disparate etiologies to low prevalence with the potential for clean efficacy signal but potentially difficult trial recruitment

• A broad set of heuristics and discussions with the research team narrowed the original list of 7 down to 3 for deeper analysis
• A range of research was conducted during the deep dive, including KOL interviews, a pipeline audit, review of trial results (benchmarking of lessons learned from recent clinical failures), and independent assessments of probabilities of success and feasibility
• Sample high-level development plans for each indication were also delivered

• A broad set of heuristics narrowed the original list of 7 down to 3 for deeper analysis
• A methodology was chosen that spanned a range of technical / scientific and commercial criteria
• A detailed overview of several key analogs provided instructive case studies
• Detailed clinical trial designs provided lessons learned at a tactical level for the clinical team
• A summary of the 3 indications provided “at a glance” scoring of strengths and weaknesses
• Sample development plans and timelines for each of the 3 finalists were created

• A top 10 global pharmaceutical company wanted to prioritize several potential secondary cardiovascular indications for a new atherosclerosis drug based on scientific, clinical, and commercial potential
• The target indication (of highest interest) is underdiagnosed and undertreated, despite high risk of cardiovascular events. Current SoC focuses on CV risk factor modification and MACE prevention; there are no treatments that prevent disease progression nor any that effectively treat symptomatic target indication

• Secondary and primary research (KOLs, “trenches” physicians, payers) to characterize the potential for the Lp-PLA2 inhibitor in each indication
• Aquest recommended pursuing target indication, driven by strong clinical potential (unique MOA, potential to address underlying atherosclerosis, and potential to treat clinically meaningful symptoms)
• Client acted on recommendation in future development

•  Current target indication drugs fall into three treatment strategies
• Physicians report fair/neutral satisfaction with drugs for target indication
• The target indication pipeline is dominated by stem cell treatments (angiogenesis)
• Target indication rated as a high investment opportunity

• A mid-size public biopharmaceutical company wanted to elucidate the largest IP-driven commercial risks to its oncology portfolio
• They also were interested in scenario planning, specifically around patent, exclusivity, targeted combination, formulation, & line extension assumptions

• Conducting a working session with client to distill their strategic priorities into a discrete set of project objectives that would give them the answer
• Created a user-friendly Excel model that could handle many IP, commercial, & global assumptions
• Mined sensitivity scenarios for new insights and strategic recommendations

• Interactive, user-friendly Excel model
• Financial impact by scenario and over time
• Dynamic timeline of IP protection

New insights about IP and the portfolio

• Identified assets with the strongest commercial position from an IP perspective and under a range of market and policy scenarios
• Identified assets with significant liabilities due to one or more IP-driven factors
• Built user-friendly model to evaluate new assets as they enter the portfolio or have commercial assumptions updated
• Translated the newly mined data into strategic insights for the portfolio